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Loss of synaptic Zn2+ transporter 
function increases risk of febrile 
seizures
Michael S. Hildebrand1,*, A. Marie Phillips2,3,*, Saul A. Mullen2,*, Paul A. Adlard2, 
Katia Hardies4,5, John A. Damiano1, Verena Wimmer2, Susannah T. Bellows1, 
Jacinta M. McMahon1, Rosemary Burgess1, Rik Hendrickx4, Sarah Weckhuysen4,5, 
Arvid Suls4,5, Peter De Jonghe4,5,7, Ingrid E. Scheffer1,2,6, Steven Petrou2, 
Samuel F. Berkovic1 & Christopher A. Reid2
Febrile seizures (FS) are the most common seizure syndrome and are potentially a prelude to more 
severe epilepsy. Although zinc (Zn2+) metabolism has previously been implicated in FS, whether or 
not variation in proteins essential for Zn2+ homeostasis contributes to susceptibility is unknown. 
Synaptic Zn2+ is co-released with glutamate and modulates neuronal excitability. SLC30A3 encodes 
the zinc transporter 3 (ZNT3), which is primarily responsible for moving Zn2+ into synaptic vesicles. 
Here we sequenced SLC30A3 and discovered a rare variant (c.892C > T; p.R298C) enriched in FS 
populations but absent in population-matched controls. Functional analysis revealed a significant 
loss-of-function of the mutated protein resulting from a trafficking deficit. Furthermore, mice null for 
ZnT3 were more sensitive than wild-type to hyperthermia-induced seizures that model FS. Together 
our data suggest that reduced synaptic Zn2+ increases the risk of FS and more broadly support the 
idea that impaired synaptic Zn2+ homeostasis can contribute to neuronal hyperexcitability.
Febrile seizures (FS) are the most common seizure syndrome, affecting 2–3% of children in the pre-school 
years1. FS account for over 1 in 200 paediatric emergency department (ED) admissions manifesting in 
physical, psychological, and behavioural issues2. They may also be associated with more severe forms of 
epilepsy in later life with long-term studies indicating that 7% of children with FS subsequently develop 
epilepsy3. Despite the clinical burden little progress in understanding the causes of FS has been made 
over the last decade, making this area a key research priority for the epilepsy field4.
Several studies support the idea that low zinc (Zn2+) levels increase seizure susceptibility. For exam-
ple, altering dietary Zn2+ intake can alter seizure susceptibility in a genetic mouse model of epilepsy, with 
low Zn2+ increasing sensitivity and high Zn2+ being protective5. Furthermore, rats administered intra-
peritoneal injections of the Zn2+ chelator sodium diethyldithiocarbamate develop seizures6. Importantly, 
Zn2+ levels are significantly lower in blood and/or cerebrospinal fluid of children that suffer FS; both 
when compared to healthy controls and when compared to children either presenting with fever alone 
or seizures not associated with fever7–10. These studies highlight dysfunction of Zn2+ homeostasis as a 
potential mechanism of enhanced FS susceptibility.
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Genetic factors play an important role in determining FS susceptibility11,12. However, whether or not 
genetic variation in proteins essential for Zn2+ homeostasis contributes to FS susceptibility is not known. 
Zn2+ transporter 3 (ZNT3), encoded by SLC30A3, is well placed to modulate neuronal excitability. ZNT3 
is primarily responsible for the transport of Zn2+ into synaptic vesicles where it is co-localised with 
glutamate and released in an activity-dependent manner13,14. High Zn2+ concentrations can occur in the 
extracellular space potentially regulating pre- and post-synaptic membrane excitability by modulating a 
variety of ion channels, receptors and transporters15. Synaptic Zn2+ released during short trains of activ-
ity inhibits NMDA receptors and hence acts as an important inhibitor of hippocampal neuronal circuit 
excitability14. Consistent with this, ZnT3 knock-out mice display increased susceptibility to pharmaco-
logical pro-convulsants16. Thus reduction in synaptic Zn2+ may increase neuronal excitability and con-
sequently seizure susceptibility. Based on the central role of synaptic Zn2+ in modulating hippocampal 
excitability and clinical evidence implicating low cerebrospinal fluid and blood levels in FS we hypoth-
esised that variation in ZNT3 would contribute to FS susceptibility. To address this we took a candidate 
gene approach, screened SLC30A3, and functionally validated a variant enriched in FS patients.
Results
ZNT3 sequencing reveals a R298C variant enriched in FS patients. Our screen of FS probands 
for variants in the coding and splice site regions of SLC30A3, encoding human ZNT3, revealed a variant 
(c.892C > T; p.R298C) in the cytoplasmic domain (Fig.  1a,c). This variant is enriched in FS probands 
(n = 3/286; 1%) and absent from population-matched controls (n = 0/643, P < 0.05, Fisher test). Two 
probands were from Australia (Probands 1 and 2) and one from Belgian (Proband 3). The variant is 
reported at over 10-fold lower frequency amongst the 6,491 exomes on the Exome Variant Server (0.09%; 
EVS; http://evs.gs.washington.edu/EVS/) and the 60,386 exomes on the Exome Aggregation Database 
(~0.08%; ExAC; http://exac.broadinstitute.org/).
The case-control analysis of this variant in FS probands against the EVS gives an odds ratio of 11 (CI 
2–37). Given a lifetime prevalence of 2–3%, the 10 fold increase in risk implied by this odds ratio would 
lead to an absolute risk of over 1 in 5 of developing FS. High Grantham (180) and PolyPhen-2 (0.995/1) 
scores also suggest that the variant is probably damaging to the ZNT3 protein. Furthermore, the amino 
acid change occurs in a highly conserved region of the cytoplasmic domain (Fig.  1b,c) and SLC30A3 
has low tolerance to variation (intolerance score = − 0.8; 12th percentile)17. The variant substitutes a 
Figure 1. Enrichment of SLC30A3 variant in FS. (a) Sequence chromatogram showing the c.892C > T 
SLC30A3 variant enriched in FS patients. (b) Multiple species alignment of ZNT3 protein sequence showing the 
R298 amino acid is highly conserved (arrow). Rhesus = Rhesus monkey; Prairie = Prairie vole. (c) Schematic 
showing domain structure of the ZNT3 protein. Light-blue shading indicates domains involved in Zn2+ 
binding. The R298C variant is located in the cytoplasmic domain near the C-terminus. Adapted from40.
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positively charged, polar arginine residue at position 298 with a cysteine residue possessing a thiol side 
chain that is susceptible to oxidation and may form disulphide bonds with other cysteine residues.
Inheritance of the R298C variant. All three probands had simple FS. A twin cohort made up a 
significant component of the sample (37/259) and probands 1 and 2 both have a monozygotic twin 
who has the R298C allele. The twin of proband 1 is unaffected while the twin of proband 2 had afebrile 
focal dyscognitive seizures in childhood (Fig. 2). Both inherited the variant from an unaffected parent. 
Proband 3 inherited the variant (Fig. 2) from her father, who was affected with febrile seizures intermixed 
with afebrile seizures until the age of 14 (febrile seizures plus, FS+ ). A brother was also affected with 
FS while there are another 4 unaffected carriers of the allele. Overall, the phenotypes in the relatives 
strengthen the argument that R298C is a risk allele rather than a Mendelian dominant allele, and sug-
gest an association with epilepsies wider than simply FS. Marker analysis was performed on the three 
probands and available relatives using microsatellites at the SLC30A3 locus (Supplementary Table 1). This 
Figure 2. Pedigrees of probands carrying ZNT3 variant. All three probands carry the c.892C > T 
(p.R298C) variant in SLC30A3. The segregation of the variants in their respective pedigrees is shown: 
*heterozygous c.892C > T (p.R298C) genotype (C/T); wt, homozygous wild-type genotype (C/C).
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revealed a small region of between 1.84 Kb and 1.50 Mb shared by all three probands (1, 2 and 3), and 
a larger region of between 1.03 Mb and 1.76 Mb shared by only the two Australian probands (1 and 2).
ZNT3 (R298C) causes a trafficking deficit resulting in severe loss-of-function. We developed a 
functional assay based on an established method in which ZNT3 is transfected into rat pheochromocy-
toma (PC12) cells18. Endogenous ZNT3 is present at only low level in PC12 cells and transfected ZNT3 
protein traffics to synaptic-like microvesicle (SLMV) membranes providing a robust system to assay 
transporter function. To validate the SLMV enrichment method untransfected PC12 cells were fraction-
ated by differential centrifugation to separate nuclear, endosomal/mitochondrial and SLMV fractions19. 
The three fractions were lysed and equal concentrations of protein from each fraction used, separated 
by SDS PAGE and Western blotted. Ponceau staining was used to verify the equivalence of protein 
Figure 3. Functional analysis reveals a loss-of-function due to the ZNT3 (R298C) variant. ai. Western 
blot analysis of the three fractions isolated by differential centrifugation including: cell/nuclear (Nucl.), 
endosomal/mitochondrial (Endo) and synaptic –like microvesicle (SLMV) fractions. Cross-reactivity with 
synaptophysin (SYP) and vGlut1 antibodies is greatest in the P3 (200,000 g) fraction confirming SLMV 
enrichment. aii Confocal images of representative PC12 cells transfected with eGFP, ZNT3 (WT)-eGFP 
and ZNT3 (R298C)-eGFP. Scale bar = 15 μ m (b) Median eGFP fluorescence in PC12 cells transfected with 
ZNT3 (WT) and ZNT3 (R298C) confirming similar ZnT3 translation from both constructs (p = 0.74, n = 4, 
Student’s paired t-test).(c) Normalized Zn2+ concentration in the SLMV fraction of ZNT3 (WT) and ZNT3 
(R298C) transfected PC12 cells from four independent experiments. Zn2+ was significantly reduced in 
ZNT3 (R298C) SLMVs (*p = 0.0013, n = 4, Student’s ratio paired t-test) (d) Mean fluorimetry measurements 
of eGFP in the SLMV fraction of ZNT3 (WT) and ZNT3 (R298C) transfected and in non-transfected 
PC12 cells. Fluorescence was significantly reduced in ZNT3 (R298C) relative to ZNT3 (WT) and was 
indistinguishable from auto-fluorescence in non-tranfected cells (*p = 0.0001, n = 3 for all groups, One way 
ANOVA).
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concentration and transfer before probing with anti-synaptophysin1 and anti-v-glut1 antibodies. Signal 
was strongest in the SLMV fraction consistent with micro-vesicle enrichment (Fig. 3ai).
In four independent experiments, duplicate flasks of PC12 cells were transiently transfected with 
either wild-type ZNT3 (WT) or mutant ZNT3 (R298C) both tagged with eGFP (Fig. 3aii). To overcome 
low transfection efficiency, whole cells expressing eGFP were sorted using FACS. Mean eGFP fluores-
cence per cell was equal for ZNT3 (WT) and ZNT3 (R298C) suggesting similar translation of both 
proteins (Fig. 3b). The isolated whole PC12 cells containing eGFP were mechanically lysed and the cell 
contents fractionated by differential centrifugation to obtain the SLMV enriched fraction. Zn2+ concen-
tration was directly measured in the SLMV using mass spectrometry, and showed a significantly lower 
Zn2+ concentration in cells transfected with ZNT3 (R298C) when compared to ZNT3 (WT) transfected 
cells (Fig. 3c). These results suggest a loss of transporter function.
eGFP-tagging provides an opportunity to measure the amount of ZNT3 protein present in the SLMV 
fraction using fluorimetry. In the SLMV fraction a significantly lower fluorescence signal was evident for 
ZNT3 (R298C) compared with ZNT3 (WT) (Fig. 3d). ZNT3 (R298C) fluorescence in the SLMV fraction 
was equivalent to a similar fraction isolated from untransfected cells suggesting an almost complete loss 
of trafficking of the mutant protein to the vesicle membrane (Fig. 3d).
ZnT3 null mice have heightened susceptibility to heat-mediated seizures. Genetic mouse 
models of epilepsy based on human FS mutations are more sensitive to heat-induced seizures validating 
the environmental heating assay20–23. Wild-type and ZnT3 knock-out mice do not differ in gross weight 
ruling out this confound as a potential basis of differential seizure susceptibility (6.5 ± 0.2 g WT, n = 8 
vs. 6.5 ± 0.6 g, KO, n = 11, p > 0.95). Kaplan-Meier survival curve analysis shows that ZnT3 null mice 
develop heat-mediated clonic-tonic seizure in a significantly shorter time than wild-type mice (Fig. 4). 
Similarly, average time to clonic-tonic seizure was significantly faster for ZnT3 null mice (694 ± 73 s WT, 
n = 8 vs. 510 ± 37 s, KO, n = 11, p = 0.03). This is consistent with low synaptic Zn2+ levels increasing 
susceptibility to FS.
Discussion
We identify the ZNT3 (R298C) variant and show it to be enriched in human FS populations. Although 
the association does not reach genome wide significance, functional analysis in PC12 cells revealed 
the variant causes loss-of-function through a trafficking deficit. This loss-of-function is highly likely to 
predispose to FS as mice null for ZnT3 protein have a heightened sensitivity to thermogenic seizures. 
Collectively this data strongly implicate ZNT3 as a susceptibility gene in FS and more generally Zn2+ 
homeostasis as a critical modulator of neuronal excitability.
Genetic factors play an important role in FS susceptibility with about 25% of FS patients having a 
family history12. Furthermore, monozygotic twins have a higher FS concordance than dizygotic twins, 
strongly implicating a genetic component11. The familial epilepsy syndrome most closely associated with 
FS is genetic epilepsy with febrile seizures plus (GEFS+ ). FS+ are distinct from FS because they occur 
outside the usual 6 months to 6 years age range and are often intermixed with afebrile seizures24. In 
families with GEFS + mutations have been identified in sodium channel subunit genes, most commonly 
SCN1A but also SCN9A and SCN1B, as well as the GABA receptor subunit GABRG2 and the presynaptic 
protein syntaxin 1B (STX1B)25–29.
For the more common simple FS, much less of the genetic contribution is known. A genome-wide 
association study showed a number of common variant associations with FS, all with odds ratios under 
Figure 4. ZnT3 null mice have heightened sensitivity to heat-induced clonic-tonic seizures. Kaplan-Meier 
curves showing time to first tonic-clonic seizure during exposure to heat for wild-type and ZnT3 knock-out 
mice homozygous are significantly different (p = 0.01, wild-type, n = 8; ZnT3, n = 11; Mantel-Cox test).
www.nature.com/scientificreports/
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230. Two SNPs were replicated in the study, one in the known epilepsy gene SCN1A and another in a 
transmembrane protein of as yet unclear function, ANO3. Two further SNPs were associated overall 
but not replicated, one in SCN2A and the other in a non-coding region implicated as a quantitative 
trait loci for serum Mg2+ levels. Furthermore, a quantitative trait locus-based study of sensitivity to 
environmental-heat induced seizures in mice found an association between seizure susceptibility and 
Srp9, which encodes a cytoplasmic ribonucleoprotein complex31. Subsequent analysis in humans showed 
an association of a SRP9 promoter region SNP with both FS and temporal lobe epilepsy31. Variation in 
Fgf13, HCN2, and KCC2 have also been implicated in FS32–35. Our findings add to these reports indicat-
ing that a variant in ZNT3 causing loss-of-function acts as a risk allele of moderate effect rather than a 
SNP of small effect or a dominant Mendelian allele.
The cellular assays confirm that the R298C variant leads to a marked loss of ZNT3 function. Given the 
equivalent translation of both ZNT3 (WT) and ZNT3 (R298C) proteins in PC12 cells, the lack of expres-
sion of ZNT3 (R298C) in the SLMV fraction points to a specific trafficking deficit. ZNT3 forms homod-
imers which are critical for the correct subcellular localization18. Interestingly, Salazar and colleagues 
showed that reducing dimerization of ZNT3 reduced trafficking to the SLMV fraction. Site-directed 
mutagenesis isolated the carboxy-terminus as a critical regulator of dimerization18. The ZNT3 (R298C) 
variant falls within the carboxy-terminus and is therefore well placed to disrupt dimerization, although 
future studies are required to determine the molecular basis of the trafficking deficit.
Multiple potential mechanisms may underlie increased excitability as extracellular Zn2+ interacts with 
a range of ion channels, receptors and transporters15,36–38. NMDA receptors, however, stand out as a tar-
get for Zn2+ because of their high sensitivity with levels as low as 10 nM producing significant inhibition 
under specific conditions39. Indeed, activity-dependent release of Zn2+ at hippocampal synapses mod-
ulates NMDA-mediated excitability14. This impact on excitability was limited to higher stimulation fre-
quencies, a situation likely to occur during neuronal hyperexcitability induced by fever40. Here we show 
that ZnT3 knock-out mice are more sensitive to heat-induced seizures, a phenomenon we have previ-
ously shown to model a human FS phenotype. Importantly, Vergnano and colleagues demonstrated that 
trains of evoked NMDA receptor-mediated synaptic events are significantly larger in the ZnT3 knock-out 
mouse14. We propose a model of pathogenesis in which heat-mediated increases in hippocampal neu-
ronal excitability are not constrained in patients harbouring ZNT3 (R298C) due to reduced inhibition 
of NMDA receptors by Zn2+.
Environmental Zn2+ deficiency also appears to predispose to FS. Several clinical studies report low 
blood and CSF Zn2+ levels in children who have been diagnosed with FS7–10. Our results provide the 
first genetic evidence that disruption in Zn2+ homeostasis can lead to an increased FS susceptibility. 
Interestingly, da Rocha and colleagues reported that serum Zn2+ levels appear to be influenced by a 
common SLC30A3 variant, although the mechanistic basis of this is unclear41. This cements the idea that 
low Zn2+ levels confer FS susceptibility through both environmental and genetic means.
Materials and Methods
Clinical Evaluation and Patient Sample. All experimental protocols were approved by The Human 
Research Ethics Committee of Austin Health, Melbourne, Australia, and the Commission for Medical 
Ethics of the University of Antwerp, Antwerp, Belgium. All methods were carried out in accordance 
with the approved guidelines of The Human Research Ethics Committee of Austin Health, Melbourne, 
Australia, and the Commission for Medical Ethics of the University of Antwerp, Antwerp, Belgium. 
Informed consent was obtained from all human subjects. A comprehensive assessment of each patient 
was obtained using a validated seizure questionnaire, clinical evaluation by an experienced epileptol-
ogist, and review of relevant medical records and clinical investigations. Where possible patients also 
underwent neurological and general medical examination. Previous clinical records and reports of rel-
evant investigations were obtained if available. We studied 286 unrelated patients of European ancestry 
recruited from Australia or Belgium diagnosed with FS and 643 control individuals without FS from 
the same populations. Whole blood was obtained and genomic DNA extracted using a Qiagen QIAamp 
DNA Maxi Kit (Valencia, CA).
PCR, Sanger Sequencing and Marker Analysis. The SLC30A3 gene was amplified using 
gene-specific primers (oligonucleotides available on request) designed to the full-length reference human 
gene transcript (NM_003459; NCBI Gene http://www.ncbi.nlm.nih.gov/). Amplification reactions were 
cycled using a standard protocol on a Veriti Thermal Cycler (Applied Biosystems, Carlsbad, CA) at 
60 °C annealing temperature for 1 minute. Bidirectional sequencing of all exons and flanking regions 
was completed with a BigDyeTM v3.1 Terminator Cycle Sequencing Kit (Applied Biosystems), accord-
ing to the manufacturer’s instructions. Sequencing products and microsatellite markers were resolved 
using a 3730xl DNA Analyzer (Applied Biosystems). All sequencing chromatograms were compared to 
published cDNA sequence; nucleotide changes were detected using Codon Code Aligner (Codon Code 
Corporation, Dedham, MA).
DNA constructs and mutagenesis. A clone of human SLC30A3 (ZNT3) CDS (NCB1 XM_006712100) 
in pUC 57 was obtained from GenScript (Piscataway, NJ, USA). PCR was used to introduce the variant 
into this construct, and the construct was tagged at the carboxy-terminal with eGFP. Tagged constructs 
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were inserted into a pCDNA 3.1 vector. DNA for transfection was assessed for integrity and quantitated 
by both Nano-drop 2000 (Thermo Scientific) and gel electrophoresis. OD260/280 ratios were 1.85–1.86. 
For transfection DNA was diluted to 1 ug/ul in sterile water.
Cell Culture. Pheochromocytoma (PC12) cells were grown and maintained in Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 10% Fetal bovine serum (FBS), 5% horse serum and 1% 
Penicillin-Streptomycin and held at 37 oC in 5% CO2. Cells were transfected by electroporation (AMAXA 
Cell Line Nucleofector kit V, Lonza, Basel, Switzerland). After 72 hours they were exposed to 25 μ M 
ZnSO4 (in DMEM) and incubated for 1 hour followed by 3 washes in phosphate-buffered saline (PBS). 
Cells were detached enzymatically (Accutase, Sigma Aldrich, Australia), pelleted, and resuspended in 
cell-sorter medium (PBS supplemented with 2% FBS and 1.5 mM EDTA). Non-transfected cells were 
used as a control. A 3 × 106 cells/ml−1 suspension was prepared for flow cytometry. Transfected cells 
were then separated by Fluorescence Activated Cell Sorting (FACS) using a BD Aria 111 cell sorter (BD 
Biosciences, San Jose, CA, USA).
Cell fractionation. FACS sorted cells were pelleted and resuspended in intracellular buffer (150 mM 
NaCl, 10 mM HEPES pH 7.4, 1 mM MgCl2, and Complete protease inhibitors (Roche, Basel, Switzerland)) 
and lysed by sonication for 1 second. Cell lysis was confirmed by microscopy. The lysates were frac-
tionated by differential centrifugation as described previously19. Briefly, the lysed cells were centrifuged 
at 1000 g for 15 minutes to generate a nuclear pellet and the supernatant subsequently centrifuged at 
27,000 g for 45 minutes, generating an endosomal/mitochondrial pellet with the final supernatant centri-
fuged at 200,000 g for 90 minutes to obtain a synaptic–like microvesicle (SLMV) enriched fraction. The 
SLMV enriched fractions were stored at − 80 °C.
Imaging. Transfected PC12 cells were fixed in 2% paraformaldehyde for 20 minutes and mounted for 
imaging analysis. Confocal images were obtained using a Zeiss LMS 800 (Zeiss, Jena, Germany) micro-
scope using excitation and emission wavelengths optimised for eGFP.
Zn2+ Analysis. Detergent lysed SLMV’s, from equal numbers of fractionated cells, were digested 
in concentrated high purity nitric acid (Aristar; BDH, London, UK) overnight at room temperature, 
and then at 90 °C for 20 minutes. Samples were diluted with 1% nitric acid, and measurements made 
using a Varian UltraMass inductively coupled plasma mass spectroscopy (ICPMS) instrument (PaloAlto, 
CA ,USA) under operating conditions suitable for routine multi-element analysis. The instrument 
was calibrated using blank, 10, 50, and 100 ppb of a certified multi-element ICPMS standard solution 
(ICP-MS-CAl2-1; AccuStandard) for Mn2+, Fe2+, Cu2+, and Zn2+ in 1% nitric acid. Results were obtained 
from four independent experiments. Mn2+ and Fe2+ were below levels of detection and Cu2+ values 
were inconsistent across the experimental groups. Zn2+ concentrations were untransfected < transfected 
mutant < transfected wild-type in all experiments. Zn2+ in un-transfected cells was deducted from the 
values in transfected cells prior to analysis. Comparisons between wild-type and mutant were made 
within experiments, with the wild-type value set as 1.
Fluorimetry of SLMV fraction. ZNT3 levels in the samples were assayed in duplicate samples by 
eGFP fluorimetry in a black-walled 384 well plate in the Polarstar Omega Plate Reader (BMG Labtech, 
Offenburg, Germany). Protocol parameters were: excitation 485–12, emission 520 and gain set at 3077. 
eGFP protein in lysis buffer was used to generate a standard curve to ensure readings fell in an assayable 
range.
Western blotting. Western blotting was carried out according to a previously published method42. 
Protein concentration in samples was assayed by the Bradford method (BioRad, Hercules, CA, USA) and 
equal protein concentrations from each fraction (80 μ g) were separated by electrophoresis on a 12% SDS 
poly-acrylamide gel, transferred to nitrocellulose by semi-dry Western blotting, and the filter stained 
with Ponceau S (Sigma, St Louis MO, USA) to confirm successful, even and equivalent protein trans-
fer. Anti-synaptophysin1, 1:3000 (Synaptic Systems, Goettingen, Germany), and anti-vglut1, 1:500 (ab 
104899, Abcam, Cambridge UK) primary antibodies and anti-rabbit HRP conjugated 1:3000 (BioRad, 
Hercules, CA, USA) and anti-sheep/goat HRP conjugated 1:1000 (Silenus, Amrad, Melbourne, Australia) 
secondary antibodies were used to confirm SLMV enrichment.
Thermogenic Seizure Testing. All animal experimentation was performed in accordance with 
ethics approval obtained from the Florey Institute of Neuroscience and Mental Health Animal Ethics 
Committee. Post-natal 16–17 mice were placed in a container heated to constant 41–42 °C and the time 
to first tonic-clonic seizure recorded20. Mice were sacrificed immediately after the first observed seizure 
to comply with our animal ethics approval. Comparisons were made between ZNT3 knock-out and their 
wild-type littermates43.
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Statistical analysis. Statistical analysis for association was Fisher’s Exact Test calculated in R (version 
2.10, http://R-project.org). Survival curves for each group were analysed using the Mantel-Cox method 
(GraphPad, CA, USA). Analysis for average time to seizure was completed using an unpaired t-test 
(GraphPad). Statistical analysis for the functional study used paired t-tests and one way ANOVA as 
appropriate, see Figure legends (GraphPad). P < 0.05 was set as significant. Graphs are mean ± standard 
error of the mean.
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